News | Structural Heart Occluders | February 13, 2019

Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder

Two-week-old patient is world's first to receive transcatheter device for patent ductus arteriosus (PDA) after recent FDA approval

Le Bonheur Children's Hospital Implants First Abbott Amplatzer Piccolo Occluder

February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo Occluder, the world's first commercially-approved medical device for transcatheter patent ductus arteriosus (PDA) closure in babies weighing as little as two pounds. The self-expanding, wire mesh device developed by Abbott is inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening of the heart.

Shyam Sathanandam, M.D., medical director of Le Bonheur's Interventional Cardiac Imaging and Interventional Catheterization Laboratory, helped pioneer the transcatheter closure before joining an eight-site U.S. Food and Drug Administration (FDA)-approved trial for the Amplatzer Piccolo Occluder used in the closure. Le Bonheur enrolled more neonates than any other center in the study.

Shyam and his team closed the PDA in the first patient post-approval, a two-week-old baby girl, born at 28 weeks and weighing 1 kilogram.

Abbott's Piccolo device is smaller than a pea and now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.

Approximately 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000 (one out of five) of these have a significant PDA which will require urgent treatment for the baby to survive.

For more information: www.abbott.com

Related Content

News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...